Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice

Clinical and Experimental Immunology

Volumn 170, Issue 2, 2012, Pages 139-148

  Alkhamis, T ^a,d   Barbic, J ^d   Crnogorac Jurcevic, T ^c   Greenlaw, R E ^a   Peakman, M ^b   Jurcevic, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

Author keywords

CD25; CD70; CD8; Islet infiltration; Non obese diabetic (NOD) mice

Indexed keywords

CD70 ANTIGEN; CD8 ANTIGEN; GLUCOSE; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FR70; MONOCLONAL ANTIBODY PC6153; MONOCLONAL ANTIBODY YTS169; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD GLUCOSE MONITORING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG TARGETING; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; LIFESPAN; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD; ANTIGENS, CD70; ANTIGENS, CD8; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; HYPERGLYCEMIA; INFLAMMATION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISLETS OF LANGERHANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; T-LYMPHOCYTES;

EID: 84867208422     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04651.x     Document Type: Article

References (50)

1. Haskins K, McDuffie M. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 1990; 249:1433-6.
2. Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 1987; 166:823-32.
3. Wong FS, Visintin I, Wen L, Flavell RA, Janeway CA Jr. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 1996; 183:67-76.
4. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003; 14:2402-10.
5. Shoda LK, Young DL, Ramanujan S etal. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005; 23:115-26.
6. Greenlaw RE, Gardner NJ, Farrar CA etal. An antibody combination that targets activated T cells extends graft survival in sensitized recipients. Am J Transplant 2008; 8:2272-82.
7. Vincenti F, Kirkman R, Light S etal. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338:161-5.
8. Wynn D, Kaufman M, Montalban X etal. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9:381-90.
9. Boursalian TE, McEarchern JA, Law CL, Grewal IS. Targeting CD70 for human therapeutic use. Adv Exp Med Biol 2009; 647:108-19.
10. Bicho A, Peca IN, Roque AC, Cardoso MM. Anti-CD8 conjugated nanoparticles to target mammalian cells expressing CD8. Int J Pharm 2010; 399:80-6.
11. Shariff H, Tanriver Y, Brown KL etal. Intermittent antibody-based combination therapy removes alloantibodies and achieves indefinite heart transplant survival in presensitized recipients. Transplantation 2010; 90:270-8.
12. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010; 160:176-84.
13. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 2004; 4:989-97.
14. Goudy KS, Burkhardt BR, Wasserfall C etal. Systemic overexpression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J Immunol 2003; 171:2270-8.
15. Ogasawara K, Hamerman JA, Ehrlich LR etal. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004; 20:757-67.
16. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999; 5:601-4.
17. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23:447-85.
18. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9:1202-8.
19. Keymeulen B, Vandemeulebroucke E, Ziegler AG etal. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-608.
20. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363:925-31.
21. Tarbell KV, Petit L, Zuo X etal. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 2007; 204:191-201.
22. Herold KC, Hagopian W, Auger JA etal. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-8.
23. Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 2010; 32:488-99.
24. Ryan MC, Kostner H, Gordon KA etal. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer 2010; 103:676-84.
25. Fiorina P, Vergani A, Dada S etal. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 2008; 57:3013-24.
26. Xiu Y, Wong CP, Bouaziz JD etal. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol 2008; 180:2863-75.
27. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H etal. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-52.
28. Chatenoud L. Immune therapy for type 1 diabetes mellitus - what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 2010; 6:149-57.
29. Hargreaves RE, Monk NJ, Jurcevic S. Selective depletion of activated T cells: the CD40L-specific antibody experience. Trends Mol Med 2004; 10:130-5.
30. Muller YD, Mai G, Morel P etal. Anti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantation. PLoS ONE 2010; 5:e10352.
31. Shariff H, Greenlaw RE, Meader L etal. Role of the Fc region in CD70-specific antibody effects on cardiac transplant survival. Transplantation 2011; 92:1194-201.
32. Demirci G, Strom TB, Li XC. Islet allograft rejection in nonobese diabetic mice involves the common gamma-chain and CD28/CD154-dependent and -independent mechanisms. J Immunol 2003; 171:3878-85.
33. de Jersey J, Snelgrove SL, Palmer SE etal. Beta cells cannot directly prime diabetogenic CD8 T cells in nonobese diabetic mice. Proc Natl Acad Sci USA 2007; 104:1295-300.
34. Wallberg M, Wong FS, Green EA. An islet-specific pulse of TGF-beta abrogates CTL function and promotes beta cell survival independent of Foxp3+ T cells. J Immunol 2011; 186:2543-51.
35. Zheng XX, Gao W, Donskoy E etal. An antagonist mutant IL-15/Fc promotes transplant tolerance. Transplantation 2006; 81:109-16.
36. Trudeau JD, Kelly-Smith C, Verchere CB etal. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 2003; 111:217-23.
37. Anderson B, Park BJ, Verdaguer J, Amrani A, Santamaria P. Prevalent CD8(+) T cell response against one peptide/MHC complex in autoimmune diabetes. Proc Natl Acad Sci USA 1999; 96:9311-6.
38. Santamaria P. Kinetic evolution of a diabetogenic CD8+ T cell response. Ann NY Acad Sci 2003; 1005:88-97.
39. Moore A, Grimm J, Han B, Santamaria P. Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes 2004; 53:1459-66.
40. Iwakoshi NN, Markees TG, Turgeon N etal. Skin allograft maintenance in a new synchimeric model system of tolerance. J Immunol 2001; 167:6623-30.
41. Bettini M, Vignali DA. T cell-driven initiation and propagation of autoimmune diabetes. Curr Opin Immunol 2011; 23:754-60.
42. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.
43. Gonzalez A, Andre-Schmutz I, Carnaud C, Mathis D, Benoist C. Damage control, rather than unresponsiveness, effected by protective DX5+ T cells in autoimmune diabetes. Nat Immunol 2001; 2:1117-25.
44. Irving-Rodgers HF, Ziolkowski AF, Parish CR etal. Molecular composition of the peri-islet basement membrane in NOD mice: a barrier against destructive insulitis. Diabetologia 2008; 51:1680-8.
45. Koulmanda M, Strom TB. T-cell-directed treatment strategies for Type 1 diabetes and the confounding role of inflammation. Immunotherapy 2010; 2:431-6.
46. Ablamunits V, Henegariu O, Hansen JB etal. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012; 61:145-54.
47. Luo X, Tarbell KV, Yang H etal. Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2007; 104:2821-6.
48. Ly D, Mi QS, Hussain S, Delovitch TL. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol 2006; 177:3695-704.
49. Tang Q, Adams JY, Tooley AJ etal. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7:83-92.
50. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54:92-9.